TB is a global pandemic
Tuberculosis (TB) is a global disease, found in every country in the world, and is the leading infectious cause of death worldwide.

In 2018, 10 million people fell ill from TB and 1.5 million died. TB is an airborne disease that can be spread by coughing or sneezing and is the deadliest infectious disease in the world.

TB is responsible for economic devastation and feeds a cycle of poverty and illness that entraps families, communities and even entire countries. Among the most vulnerable are women, children and people living with HIV/AIDS.

There is growing resistance to available drugs, which means the disease is becoming more deadly and difficult to treat. There were about half a million cases of drug-resistant TB last year.

New TB treatments are needed
Today’s TB treatments take too long to cure, are too complicated to administer, and can be toxic. People with TB must take drugs from 6 months to 2 years or longer – or risk developing more difficult to treat drug-resistant TB.

The cost of curing drug-resistant TB can be staggering, posing a significant challenge to governments, health systems and other payers.

In August 2019, TB Alliance received approval for a new treatment for highly drug-resistant TB. This drug is only the third new anti-TB drug approved for use in more than 40 years, as well as the first to be developed and registered by a not-for-profit organization.

Our pipeline
TB Alliance’s mission is to develop better, faster and affordable TB cures. Before TB Alliance was established in 2000, there were no new TB drugs in clinical development.

Today, TB Alliance manages the largest pipeline of new TB drugs in history and has advanced multiple products to market. Our goal is to introduce new treatments that will significantly impact the TB pandemic.
Without new and improved TB treatments, we cannot defeat this deadly disease.

Our commitment
TB Alliance can only achieve its mission if new, faster-acting and better TB cures are adopted, available and affordable to those who need them. This commitment—our “AAA Mandate”—is TB Alliance’s explicit pledge to ensure that any new TB treatments developed will be used to benefit people suffering from TB and to have maximum impact on the pandemic.

The promise of new cures
Our ultimate vision is to have a transformative impact on the disease by introducing ultra-short, simple and affordable TB regimens that work in virtually all people with tuberculosis. A sustainable pipeline of combination treatments with such broad utility would have a major impact on the global epidemic, saving millions of lives.

The potential benefits of new TB cures include:

• Shorter, simpler and safer treatment, with improved adherence and fewer side effects, reducing the burden of treatment to health care systems, TB programs and patients
• Ability to treat both drug-sensitive and drug-resistant disease with the same regimen, simplifying and enabling the scale-up of therapy globally
• Affordable treatment for drug-resistant TB, at a fraction of the cost of current treatment efforts
• Compatibility with HIV/AIDS medications
• Improved treatment outcomes and patient experience
• Safe and effective TB treatments designed specifically for children

References